The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases
Source abstract
Abstract
Some of the most crucial turning points in the treatment strategies for some major infectious diseases including AIDS, malaria, and TB, have been reached with the introduction of antimicrobials and vaccines. Drug resistance and poor effectiveness are key limitations that need to be overcome. Conventional liposomes have been explored as a delivery system for infectious diseases bioactives to treat infectious diseases to provide an efficient approach to maximize the therapeutic outcomes, drug stability, targetability, to reduce the side-effects of antimicrobials, and enhance vaccine performance where necessary. However, as the pathological understanding of infectious diseases become more known, the need for more advanced liposomal technologies was born to continue having a profound effect on targeted chemotherapy for infectious diseases. This review therefore provides a concise incursion into the most recent and vogue liposomal formulations used to treat infectious diseases. An appraisal of immunological, stimuli-responsive, biomimetic and functionalized liposomes and other novel modifications to conventional liposomes is assimilated in sync with mutations of resistant pathogens.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Suhaimi NA, et al. Application of liposomes in the treatment of infectious diseases. Life Sci. 2022;305:120734. https://doi.org/10.1016/j.lfs.2022.120734.10.1016/j.lfs.2022.120734 ↗
2. van Seventer JM, Hochberg NS. Principles of infectious diseases: transmission, diagnosis, prevention and control. Int Encycl Public Health. 2017;6(2):22–39.10.1016/B978-0-12-803678-5.00516-6 ↗
3. Kurtovic L, Reiling L, Opi DH, Beeson JG. Recent clinical trials inform the future for malaria vaccines. Commun Med. 2021. https://doi.org/10.1038/s43856-021-00030-2.10.1038/s43856-021-00030-2 ↗
4. Schrager LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF. The status of tuberculosis vaccine development. Lancet Infect Dis. 2020;20(3):e28–37. https://doi.org/10.1016/S1473-3099(19)30625-5.10.1016/S1473-3099(19)30625-5 ↗
5. de Carvalho LP, Kreidenweiss A, Held J. Drug repurposing: a review of old and new antibiotics for the treatment of malaria: identifying antibiotics with a fast onset of antiplasmodial action. Molecules. 2021. https://doi.org/10.3390/molecules26082304.10.3390/molecules26082304 ↗
6. Ahmed SK, et al. Antimicrobial resistance: impacts, challenges, and future prospects. J Med Surg Public Health. 2024;2:100081. https://doi.org/10.1016/j.glmedi.2024.100081.10.1016/j.glmedi.2024.100081 ↗
7. Ferreira M, et al. Liposomes as antibiotic delivery systems: a promising nanotechnological strategy against antimicrobial resistance. Molecules. 2021. https://doi.org/10.3390/molecules26072047.10.3390/molecules26072047 ↗
8. Alhamhoom Y, et al. Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: a review. Saudi Pharm J. 2023;31(2):279–94. https://doi.org/10.1016/j.jsps.2022.12.008.10.1016/j.jsps.2022.12.008 ↗
9. Ghosh R, De M. Liposome-based antibacterial delivery: an emergent approach to combat bacterial infections. ACS Omega. 2023;8(39):35442–51. https://doi.org/10.1021/acsomega.3c04893.10.1021/acsomega.3c04893 ↗
10. Makhlouf Z, Ali AA, Al-Sayah MH. Liposomes-based drug delivery systems of anti-biofilm agents to combat bacterial biofilm formation. Antibiotics. 2023;12(5):1–32. https://doi.org/10.3390/antibiotics12050875.10.3390/antibiotics12050875 ↗
11. Wang DY, van der Mei HC, Ren Y, Busscher HJ, Shi L. Lipid-based antimicrobial delivery-systems for the treatment of bacterial infections. Front Chem. 2020;7:1–15. https://doi.org/10.3389/fchem.2019.00872.10.3389/fchem.2019.00872 ↗
12. Nwabuife JC, et al. Novel vancomycin free base—sterosomes for combating diseases caused by Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus infections (S. aureus and MRSA). J Drug Deliv Sci Technol. 2022;79:104089. https://doi.org/10.1016/j.jddst.2022.104089.10.1016/j.jddst.2022.104089 ↗
13. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015. https://doi.org/10.3389/fphar.2015.00286.10.3389/fphar.2015.00286 ↗
14. Aditya NP, Vathsala PG, Vieira V, Murthy SR, Souto EB. Advances in nanomedicines for malaria treatment. Adv Colloid Interface Sci. 2013. https://doi.org/10.1016/j.cis.2013.10.014.10.1016/j.cis.2013.10.014 ↗
15. Sharma M, et al. Liposome—a comprehensive approach for researchers. IntechOpen; 2013.
16. Kim EM, Jeong HJ. Liposomes: biomedical applications. Chonnam Med J. 2021. https://doi.org/10.4068/cmj.2021.57.1.27.10.4068/cmj.2021.57.1.27 ↗
17. Tiwari R, et al. Nanotechnology-based strategies in parasitic disease management: from prevention to diagnosis and treatment. ACS Omega. 2023;8(45):42014–27. https://doi.org/10.1021/acsomega.3c04587.10.1021/acsomega.3c04587 ↗
18. Hatae AC, Roque-Borda CA, Pavan FR. Strategies for lipid-based nanocomposites with potential activity against Mycobacterium tuberculosis: microbial resistance challenge and drug delivery trends. OpenNano. 2023. https://doi.org/10.1016/j.onano.2023.100171.10.1016/j.onano.2023.100171 ↗
19. Nair A, et al. Advanced drug delivery and therapeutic strategies for tuberculosis treatment. J Nanobiotechnol. 2023;21(1):1–31. https://doi.org/10.1186/s12951-023-02156-y.10.1186/s12951-023-02156-y ↗
20. Kumar M, et al. Nanocarriers in tuberculosis treatment: challenges and delivery strategies. Pharmaceuticals. 2023;16(10):1–38. https://doi.org/10.3390/ph16101360.10.3390/ph16101360 ↗
21. Lee MK. Liposomes for enhanced bioavailability of water-insoluble drugs: in vivo evidence and recent approaches. Pharmaceutics. 2020. https://doi.org/10.3390/pharmaceutics12030264.10.3390/pharmaceutics12030264 ↗
22. Nikolova MP, Kumar EM, Chavali MS. Updates on responsive drug delivery based on liposome vehicles for cancer treatment. Pharmaceutics. 2022;14(10):1–51. https://doi.org/10.3390/pharmaceutics14102195.10.3390/pharmaceutics14102195 ↗
23. Cagdas M, Sezer AD, and Bucak S. Liposomes as potential drug carrier systems for drug delivery. In: Application of nanotechnology in drug delivery; 2014, pp 1–51. https://doi.org/10.5772/58459.10.5772/58459 ↗
24. Nsairat H, Khater D, Sayed U, Odeh F, AlBawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8(5):e09394. https://doi.org/10.1016/j.heliyon.2022.e09394.10.1016/j.heliyon.2022.e09394 ↗
25. Gbian DL, Omri A. Lipid-based drug delivery systems for diseases managements. Biomedicines. 2022. https://doi.org/10.3390/biomedicines10092137.10.3390/biomedicines10092137 ↗
26. Lombardo SM, Schneider M, Türeli AE, Türeli NG. Key for crossing the BBB with nanoparticles: the rational design. Beilstein J Nanotechnol. 2020;11(866):866–83. https://doi.org/10.3762/BJNANO.11.72.10.3762/BJNANO.11.72 ↗
27. Akbarzadeh A, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(10):1–9.
28. Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27(4):1372.10.3390/molecules27041372 ↗
29. Venkata V, Naga S, Andra L, Lakshmi SVP, Krishna V, Bhatraju P. A comprehensive review on novel liposomal methodologies, commercial formulations. Clin Trials Patents Bionanosci. 2022;12:274–91. https://doi.org/10.1007/s12668-022-00941-x.10.1007/s12668-022-00941-x ↗
30. Fulton MD, Najahi-Missaoui W. Liposomes in cancer therapy: how did we start and where are we now. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24076615.10.3390/ijms24076615 ↗
31. Huang Y, Guo X, Wu Y, Chen X, Feng L, Xie N. Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment. Signal Transduct Target Ther. 2024. https://doi.org/10.1038/s41392-024-01745-z.10.1038/s41392-024-01745-z ↗
32. Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol. 2014;7:1–11.
33. Pasarin D, et al. Coating materials to increase the stability of liposomes. Polymers. 2023;15(3):1–30. https://doi.org/10.3390/polym15030782.10.3390/polym15030782 ↗
34. Nunes D, Loureiro JA, Pereira MC. Drug delivery systems as a strategy to improve the efficacy of FDA-approved Alzheimer’s drugs. Pharmaceutics. 2022. https://doi.org/10.3390/pharmaceutics14112296.10.3390/pharmaceutics14112296 ↗
35. Wang Z, et al. Translational challenges and prospective solutions in the implementation of biomimetic delivery systems. Pharmaceutics. 2023;15(11):1–33. https://doi.org/10.3390/pharmaceutics15112623.10.3390/pharmaceutics15112623 ↗
36. Abuwatfa WH, Awad NS, Pitt WG, Husseini GA. Thermosensitive polymers and thermo-responsive liposomal drug delivery systems. Polymers. 2022. https://doi.org/10.3390/polym14050925.10.3390/polym14050925 ↗
37. Franco MS, Gomes ER, Roque MC, Oliveira MC. Triggered drug release from liposomes: exploiting the outer and inner tumor environment. Front Oncol. 2021;11:1–23. https://doi.org/10.3389/fonc.2021.623760.10.3389/fonc.2021.623760 ↗
38. Allahou LW, Madani SY, Seifalian A. Investigating the application of liposomes as drug delivery systems for the diagnosis and treatment of cancer. Int J Biomater. 2021. https://doi.org/10.1155/2021/3041969.10.1155/2021/3041969 ↗
39. De Leo V, Milano F, Agostiano A, Catucci L. Recent advancements in polymer/liposome assembly for drug delivery: from surface modifications to hybrid vesicles. Polymers. 2021. https://doi.org/10.3390/polym13071027.10.3390/polym13071027 ↗
40. Jiang Y, Li W, Wang Z. Lipid-based nanotechnology: liposome. Pharmaceuticals. 2024;16(24).10.3390/pharmaceutics16010034 ↗
41. Agiba AM, Arreola-ram L, Carbajal V, Segura-Medina P. From mechanisms to targeting strategies. Molecules. 2024;29(636).10.3390/molecules29030636 ↗
42. Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. AAPS J. 2012;14(2):303–15. https://doi.org/10.1208/s12248-012-9330-0.10.1208/s12248-012-9330-0 ↗
43. Raju R, Abuwatfa WH, Pitt WG, Husseini GA. Liposomes for the treatment of brain cancer—a review. Pharmaceuticals. 2023. https://doi.org/10.3390/ph16081056.10.3390/ph16081056 ↗
44. Wang S, Chen Y, Guo J, Huang Q. Liposomes for tumor targeted therapy: a review. Int J Mol Sci. 2023;24(3):1–25. https://doi.org/10.3390/ijms24032643.10.3390/ijms24032643 ↗
45. Jyothi S, et al. Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: an update. Int J Pharm. 2022;624:122022. https://doi.org/10.1016/j.ijpharm.2022.122022.10.1016/j.ijpharm.2022.122022 ↗
46. Lombardo D, Kiselev MA. Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics. 2022. https://doi.org/10.3390/pharmaceutics14030543.10.3390/pharmaceutics14030543 ↗
47. Anamika J, Nikhar V, Laxmikant G, Priya S, Sonal V, Vyas SP. Nanobiotechnological modules as molecular target tracker for the treatment and prevention of malaria: options and opportunity. Drug Deliv Transl Res. 2020;10(4):1095–110. https://doi.org/10.1007/s13346-020-00770-z.10.1007/s13346-020-00770-z ↗
48. Cao Y, Dong X, Chen X. Polymer-modified liposomes for drug delivery: from fundamentals to applications. Pharmaceutics. 2022. https://doi.org/10.3390/pharmaceutics14040778.10.3390/pharmaceutics14040778 ↗
49. Thang NH, Chien TB, Cuong DX. Polymer-based hydrogels applied in drug delivery: an overview. Gels. 2023;9(7):1–38. https://doi.org/10.3390/gels9070523.10.3390/gels9070523 ↗
50. Sriwidodo A, Umar AK, Wathoni N, Zothantluanga JH, Das S, Luckanagul JA. Liposome-polymer complex for drug delivery system and vaccine stabilization. Heliyon. 2022;8(2):e08934. https://doi.org/10.1016/j.heliyon.2022.e08934.10.1016/j.heliyon.2022.e08934 ↗
51. Riaz MK, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19010195.10.3390/ijms19010195 ↗
52. Xin H, Jiang Y, Lv W, Xu J. Liposome-based drug delivery for brain tumor theranostics. Elsevier Inc.; 2018. https://doi.org/10.1016/B978-0-12-812218-1.00009-9.10.1016/B978-0-12-812218-1.00009-9 ↗
53. Nel J, et al. Functionalized liposomes for targeted breast cancer drug delivery. Bioact Mater. 2022;24:401–37. https://doi.org/10.1016/j.bioactmat.2022.12.027.10.1016/j.bioactmat.2022.12.027 ↗
54. Wang C, et al. Construction strategy of functionalized liposomes and multidimensional application. Small. 2024. https://doi.org/10.1002/smll.202309031.10.1002/smll.202309031 ↗
55. Bombelli C, et al. New cationic liposomes as vehicles of m-tetrahydroxyphenylchlorin in photodynamic therapy of infectious diseases. Mol Pharm. 2008;5(4):672–9. https://doi.org/10.1021/mp800037d.10.1021/mp800037d ↗
56. Liu X, et al. Novel antimicrobial peptide—modified azithromycin-loaded liposomes against methicillin-resistant Staphylococcus aureus. Int J Nanomed. 2016;11:6781–94. https://doi.org/10.2147/IJN.S107107.10.2147/IJN.S107107 ↗
57. Mutalik SP, et al. Anti-CD4 antibody and dendrimeric peptide based targeted nano-liposomal dual drug formulation for the treatment of HIV infection. Life Sci. 2023. https://doi.org/10.1016/j.lfs.2023.122226.10.1016/j.lfs.2023.122226 ↗
58. Shao Q, et al. Protein corona mediated liposomal drug delivery for bacterial infection management. Asian J Pharm Sci. 2022;17(6):855–66. https://doi.org/10.1016/j.ajps.2022.10.003.10.1016/j.ajps.2022.10.003 ↗
59. Vanić Ž, et al. Azithromycin-liposomes as a novel approach for localized therapy of cervicovaginal bacterial infections. Int J Nanomed. 2019;14:5957–76. https://doi.org/10.2147/IJN.S211691.10.2147/IJN.S211691 ↗
60. Menina S, et al. Invasin-functionalized liposome nanocarriers improve the intracellular delivery of anti-infective drugs. RSC Adv. 2016;6(47):41622–9. https://doi.org/10.1039/c6ra02988d.10.1039/c6ra02988d ↗
61. Rose SJ, Neville ME, Gupta R, Bermudez LE. Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection. PLoS ONE. 2014;9(9):1–7. https://doi.org/10.1371/journal.pone.0108703.10.1371/journal.pone.0108703 ↗
62. Zhao Z, et al. A novel liposome-polymer hybrid nanoparticles delivering a multi-epitope self-replication DNA vaccine and its preliminary immune evaluation in experimental animals. Nanomed Nanotechnol Biol Med. 2021;35:102338. https://doi.org/10.1016/j.nano.2020.102338.10.1016/j.nano.2020.102338 ↗
63. Garcia CB, Shi D, Webster TJ. Tat-functionalized liposomes for the treatment of meningitis: an in vitro study. Int J Nanomed. 2017;12:3009–21. https://doi.org/10.2147/IJN.S130125.10.2147/IJN.S130125 ↗
64. Menina S, et al. Bioinspired liposomes for oral delivery of colistin to combat intracellular infections by Salmonella enterica. Adv Healthc Mater. 2019. https://doi.org/10.1002/adhm.201900564.10.1002/adhm.201900564 ↗
65. Meng Y, et al. Multi-functional liposomes enhancing target and antibacterial immunity for antimicrobial and anti-biofilm against methicillin-resistant Staphylococcus aureus. Pharm Res. 2016;33(3):63–775. https://doi.org/10.1007/s11095-015-1825-9.10.1007/s11095-015-1825-9 ↗
66. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 2006;1(3):297–315.
67. Nag OK, Awasthi V. Surface engineering of liposomes for stealth behavior. Pharmaceutics. 2013;5(4):42–569. https://doi.org/10.3390/pharmaceutics5040542.10.3390/pharmaceutics5040542 ↗
68. Lamichhane N, et al. Liposomes: clinical applications and potential for image-guided drug delivery. Molecules. 2018;23(2):1–17. https://doi.org/10.3390/molecules23020288.10.3390/molecules23020288 ↗
69. Singh AP, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther. 2019;4(1):1–21. https://doi.org/10.1038/s41392-019-0068-3.10.1038/s41392-019-0068-3 ↗
70. Nisini R, Poerio N, Mariotti S, De Santis F, Fraziano M. The multirole of liposomes in therapy and prevention of infectious diseases. Front Immunol. 2018. https://doi.org/10.3389/fimmu.2018.00155.10.3389/fimmu.2018.00155 ↗
71. Eleraky NE, Allam A, Hassan SB, Omar MM. Nanomedicine fight against antibacterial resistance: an overview of the recent pharmaceutical innovations. Pharmaceutics. 2020;12(2):1–51. https://doi.org/10.3390/pharmaceutics12020142.10.3390/pharmaceutics12020142 ↗
72. Taher M, et al. PEGylated liposomes enhance the effect of cytotoxic drug: a review. Heliyon. 2023;9(3):e13823. https://doi.org/10.1016/j.heliyon.2023.e13823.10.1016/j.heliyon.2023.e13823 ↗
73. Najjari Z, Sadri F, Varshosaz J. Smart stimuli-responsive drug delivery systems in spotlight of COVID-19. Asian J Pharm Sci. 2023;18(6):100873. https://doi.org/10.1016/j.ajps.2023.100873.10.1016/j.ajps.2023.100873 ↗
74. Rahim MA, et al. Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting. Cancers. 2021;13(4):1–52. https://doi.org/10.3390/cancers13040670.10.3390/cancers13040670 ↗
75. Kaul A, Chaturvedi S, Attri A, Kalra M, Mishra AK. Targeted theranostic liposomes: rifampicin and ofloxacin loaded pegylated liposomes for theranostic application in mycobacterial infections. RSC Adv. 2016;6(4):28919–26. https://doi.org/10.1039/c6ra01135g.10.1039/c6ra01135g ↗
76. Singla A, et al. Hetero-multivalent targeted liposomal drug delivery to treat Pseudomonas aureginosa infections. ACS Appl Mater Interfaces. 2022;14:40724–37. https://doi.org/10.1021/acsami.2c12943ACS.10.1021/acsami.2c12943ACS ↗
77. Ibrahim S, Tagami T, Ozeki T. Effective-loading of platinum-chloroquine into PEGylated neutral and cationic liposomes as a drug delivery system for resistant malaria parasites. Biol Pharm Bull. 2017;40(6):815–23. https://doi.org/10.1248/bpb.b16-00914.10.1248/bpb.b16-00914 ↗
78. Tripathi D, Hajra K, Maity D. Recent advancement of bio-inspired nanoparticles in cancer theragnostic. J Nanotheranostics. 2023;4(3):99–322. https://doi.org/10.3390/jnt4030014.10.3390/jnt4030014 ↗
79. Pinilla CMB, Lopes NA, Brandelli A. Lipid-based nanostructures for the delivery of natural antimicrobials. Molecules. 2021;26(12):1–22. https://doi.org/10.3390/molecules26123587.10.3390/molecules26123587 ↗
80. Feng C, Tan P, Nie G, Zhu M. Biomimetic and bioinspired nano-platforms for cancer vaccine development. Exploration. 2023. https://doi.org/10.1002/EXP.20210263.10.1002/EXP.20210263 ↗
81. Dehaini D, Fang RH, Zhang L. Biomimetic strategies for targeted nanoparticle delivery. Bioeng Transl Med. 2016;1(1):30–46. https://doi.org/10.1002/btm2.10004.10.1002/btm2.10004 ↗
82. Desai N, et al. Bioinspired’ membrane-coated nanosystems in cancer theranostics: a comprehensive review. Pharmaceutics. 2023. https://doi.org/10.3390/pharmaceutics15061677.10.3390/pharmaceutics15061677 ↗
83. Subramaniam S, Joyce P, Thomas N, Prestidge CA. Bioinspired drug delivery strategies for repurposing conventional antibiotics against intracellular infections. Adv Drug Deliv Rev. 2021;177:113948. https://doi.org/10.1016/j.addr.2021.113948.10.1016/j.addr.2021.113948 ↗
84. Rommasi F, Esfandiari N. Liposomal nanomedicine: applications for drug delivery in cancer therapy. Nanoscale Res Lett. 2021. https://doi.org/10.1186/s11671-021-03553-8.10.1186/s11671-021-03553-8 ↗
85. Cheng WW, Allen TM. The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv. 2010;7(4):461–78. https://doi.org/10.1517/17425240903579963.10.1517/17425240903579963 ↗
86. Li J, et al. Recent advances in targeted drug delivery strategy for enhancing oncotherapy. Pharmaceutics. 2023. https://doi.org/10.3390/pharmaceutics15092233.10.3390/pharmaceutics15092233 ↗
87. Faizal ND, et al. Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants. Asian J Pharm Sci. 2023;18(6):100855. https://doi.org/10.1016/j.ajps.2023.100855.10.1016/j.ajps.2023.100855 ↗
88. Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting strategies for tissue-specific drug delivery. Cell. 2020;181(1):151–67. https://doi.org/10.1016/j.cell.2020.02.001.10.1016/j.cell.2020.02.001 ↗
89. Nigam S, Ghosh PC, Sarma PU. Altered immune response to liposomal allergens of Aspergillus fumigatus in mice. Int J Pharm. 2002;236:97–109. https://doi.org/10.1016/S0378-5173(02)00013-3.10.1016/S0378-5173(02)00013-3 ↗
90. Coata-Barbosa, et al. Design of a lipid nano-delivery system containing recombinant Candida albicans chitinase 3 as a potential vaccine against fungal infections. Biomed Pharmacother. 2023;66:115362. https://doi.org/10.1016/j.biopha.2023.115362.10.1016/j.biopha.2023.115362 ↗
91. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes. Proc Natl Acad Sci. 2001;98(15):8786–91.10.1073/pnas.151247498 ↗
92. Sonju JJ, Dahal A, Singh SS, Jois SD. Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment. J Pept Sci. 2021;10(290):624–44. https://doi.org/10.1002/psc.2481.10.1002/psc.2481 ↗
93. Guo S, Wang J, Wang Q, Wang J, Qin S, Li W. Advances in peptide-based drug delivery systems. Heliyon. 2024;1094:e26009. https://doi.org/10.1016/j.heliyon.2024.e26009.10.1016/j.heliyon.2024.e26009 ↗
94. Liu M, Fang X, Yang Y, Wang C. Peptide-enabled targeted delivery systems for therapeutic applications. Front Bioeng Biotechnol. 2021;9:1–15. https://doi.org/10.3389/fbioe.2021.701504.10.3389/fbioe.2021.701504 ↗
95. Kunisawa J, et al. Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release. J Control Release. 2005;105(3):344–53. https://doi.org/10.1016/j.jconrel.2005.03.020.10.1016/j.jconrel.2005.03.020 ↗
96. Saffari M, Moghimi HR, Dass CR. Barriers to liposomal gene delivery: From application site to the target. Iran J Pharm Res. 2016;15:3–17.
97. Chen F, Bian M, Nahmou M, Myung D, Goldberg JL. Fusogenic liposome-enhanced cytosolic delivery of magnetic nanoparticles. RSC Adv. 2021;11(7):35796–805. https://doi.org/10.1039/d1ra03094a.10.1039/d1ra03094a ↗
98. Scheeder A, Brockhoff M, Ward EN, Kaminski Schierle GS, Mela I, Kaminski CF. Molecular mechanisms of cationic fusogenic liposome interactions with bacterial envelopes. J Am Chem Soc. 2023;145(51):28240–50. https://doi.org/10.1021/jacs.3c11463.10.1021/jacs.3c11463 ↗
99. Kube S, et al. Fusogenic liposomes as nanocarriers for the delivery of intracellular proteins. Langmuir. 2017;33(4):1051–9. https://doi.org/10.1021/acs.langmuir.6b04304.10.1021/acs.langmuir.6b04304 ↗
100. Kunisawa J, Nakagawa S, Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv Drug Deliv Rev. 2001;52(3):177–86. https://doi.org/10.1016/S0169-409X(01)00214-9.10.1016/S0169-409X(01)00214-9 ↗